Fig. 3. Gain-of-function of MIR22HG inhibits the proliferation and migration of breast cancer cells.
a Overexpression efficiency of MIR22HG in MDA-MB-231 and BT549 cells after transfection with MIR22HG pcDNA3.1 plasmid for 48 h. b, c MTT assay (5-day period) and colony formation assay (18-day period) were performed to determine the viability of MDA-MB-231 and BT549 cells after transfection. d Transwell assay (20-h period, 3 × 104 cells per well) was used to evaluate the migration ability of MDA-MB-231 and BT549 cells after MIR22HG overexpression (100× magnification). e A subcutaneous xenograft model was utilized to explore the biological function of MIR22HG in vivo. The MDA-MB-231 cells that stably expressed MIR22HG were subcutaneously injected into 6-week-old BALB/c nu/nu female mice. After 30 days, the tumors were collected, and the tumor volume and weight were measured. **P < 0.01, ***P < 0.001, ****P < 0.0001. All experiments were repeated thrice.